FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153032490> ?p ?o ?g. }

• W2153032490 endingPage "179" @default.
• W2153032490 startingPage "175" @default.
• W2153032490 abstract "Background Palliative and supportive care services provide excellent care to patients near the end of life. It is estimated that enrollment in such services can reduce end-of-life costs; however, there is limited data available regarding the impact of palliative services in end-of-life care in gynecologic oncology patients. We examined the use of palliative services in gynecologic oncology patients during the last six months of life. Methods After IRB approval, a retrospective chart review of patients with a diagnosis of a gynecologic malignancy who died between June 2007 and June 2010 was performed. Abstracted data included demographics, admission and procedural history, use of anti-cancer therapy, and palliative care utilization during the last six months of life. Results 268 patients were identified. Most patients were white (76.9%) and had ovarian cancer (56.7%). During the last six months of life, 155 (57.8%) patients underwent anti-cancer therapy with chemotherapy, 19 (7.1%) patients were treated with radiation therapy, and 17 patients (6.3%) underwent treatment with both. 218 patients (81.3%) had at least one admission during this time (range 0–14). The most common reason for admission was gastrointestinal complaints (37.1%), followed by admissions for procedures (18.3%). The median time between the last admission and death was 32 days. 157 patients (58.6%) underwent at least one procedure during the last six months of life (range 0–11). The most common procedure performed was paracentesis (22.6%). 198 (73.9%) patients died at home or in a palliative care unit. 189 (70.5%) patients were referred to hospice or palliative care. 3.2% underwent a procedure or treatment with chemotherapy or radiation after hospice enrollment. The median time between hospice enrollment and death was 22 days. 55% of patients were enrolled in hospice less than 30 days before death. Of the 79 patients not referred to hospice, only 16.5% had documentation of refusing hospice services. Conclusions During the last six months of life, the majority of gynecologic oncology patients receive anticancer therapy and many have repeated hospital admissions. While the majority of patients are referred for palliative care, it appears that most patients spend less than 30 days on hospice. Earlier referral could decrease the number of hospital admissions and procedures while providing invaluable support during this end of life transition." @default.
• W2153032490 created "2016-06-24" @default.
• W2153032490 creator A5006323960 @default.
• W2153032490 creator A5018884124 @default.
• W2153032490 creator A5034799601 @default.
• W2153032490 creator A5044981934 @default.
• W2153032490 creator A5046206864 @default.
• W2153032490 creator A5063352561 @default.
• W2153032490 creator A5086281773 @default.
• W2153032490 date "2012-10-01" @default.
• W2153032490 modified "2023-09-30" @default.
• W2153032490 title "The utilization of palliative care in gynecologic oncology patients near the end of life" @default.
• W2153032490 cites W1591353337 @default.
• W2153032490 cites W1965380313 @default.
• W2153032490 cites W1999513927 @default.
• W2153032490 cites W2004705294 @default.
• W2153032490 cites W2008949515 @default.
• W2153032490 cites W2022229561 @default.
• W2153032490 cites W2024660449 @default.
• W2153032490 cites W2035429031 @default.
• W2153032490 cites W2047085223 @default.
• W2153032490 cites W2054257136 @default.
• W2153032490 cites W2057799875 @default.
• W2153032490 cites W2065503548 @default.
• W2153032490 cites W20660546 @default.
• W2153032490 cites W2075257400 @default.
• W2153032490 cites W2081497438 @default.
• W2153032490 cites W2084248822 @default.
• W2153032490 cites W2085924948 @default.
• W2153032490 cites W2111558284 @default.
• W2153032490 cites W2119820904 @default.
• W2153032490 cites W2125130977 @default.
• W2153032490 cites W2147878219 @default.
• W2153032490 cites W2155095288 @default.
• W2153032490 cites W2160759345 @default.
• W2153032490 cites W2324292085 @default.
• W2153032490 cites W4241742870 @default.
• W2153032490 doi "https://doi.org/10.1016/j.ygyno.2012.06.025" @default.
• W2153032490 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22735789" @default.
• W2153032490 hasPublicationYear "2012" @default.
• W2153032490 type Work @default.
• W2153032490 sameAs 2153032490 @default.
• W2153032490 citedByCount "52" @default.
• W2153032490 countsByYear W21530324902012 @default.
• W2153032490 countsByYear W21530324902013 @default.
• W2153032490 countsByYear W21530324902014 @default.
• W2153032490 countsByYear W21530324902015 @default.
• W2153032490 countsByYear W21530324902016 @default.
• W2153032490 countsByYear W21530324902017 @default.
• W2153032490 countsByYear W21530324902018 @default.
• W2153032490 countsByYear W21530324902019 @default.
• W2153032490 countsByYear W21530324902020 @default.
• W2153032490 countsByYear W21530324902021 @default.
• W2153032490 countsByYear W21530324902022 @default.
• W2153032490 countsByYear W21530324902023 @default.
• W2153032490 crossrefType "journal-article" @default.
• W2153032490 hasAuthorship W2153032490A5006323960 @default.
• W2153032490 hasAuthorship W2153032490A5018884124 @default.
• W2153032490 hasAuthorship W2153032490A5034799601 @default.
• W2153032490 hasAuthorship W2153032490A5044981934 @default.
• W2153032490 hasAuthorship W2153032490A5046206864 @default.
• W2153032490 hasAuthorship W2153032490A5063352561 @default.
• W2153032490 hasAuthorship W2153032490A5086281773 @default.
• W2153032490 hasConcept C121608353 @default.
• W2153032490 hasConcept C126322002 @default.
• W2153032490 hasConcept C159110408 @default.
• W2153032490 hasConcept C167135981 @default.
• W2153032490 hasConcept C194828623 @default.
• W2153032490 hasConcept C2776258039 @default.
• W2153032490 hasConcept C2780427987 @default.
• W2153032490 hasConcept C2780435969 @default.
• W2153032490 hasConcept C2780496750 @default.
• W2153032490 hasConcept C2780879335 @default.
• W2153032490 hasConcept C2994186709 @default.
• W2153032490 hasConcept C2994372414 @default.
• W2153032490 hasConcept C509974204 @default.
• W2153032490 hasConcept C71924100 @default.
• W2153032490 hasConceptScore W2153032490C121608353 @default.
• W2153032490 hasConceptScore W2153032490C126322002 @default.
• W2153032490 hasConceptScore W2153032490C159110408 @default.
• W2153032490 hasConceptScore W2153032490C167135981 @default.
• W2153032490 hasConceptScore W2153032490C194828623 @default.
• W2153032490 hasConceptScore W2153032490C2776258039 @default.
• W2153032490 hasConceptScore W2153032490C2780427987 @default.
• W2153032490 hasConceptScore W2153032490C2780435969 @default.
• W2153032490 hasConceptScore W2153032490C2780496750 @default.
• W2153032490 hasConceptScore W2153032490C2780879335 @default.
• W2153032490 hasConceptScore W2153032490C2994186709 @default.
• W2153032490 hasConceptScore W2153032490C2994372414 @default.
• W2153032490 hasConceptScore W2153032490C509974204 @default.
• W2153032490 hasConceptScore W2153032490C71924100 @default.
• W2153032490 hasIssue "1" @default.
• W2153032490 hasLocation W21530324901 @default.
• W2153032490 hasLocation W21530324902 @default.
• W2153032490 hasOpenAccess W2153032490 @default.
• W2153032490 hasPrimaryLocation W21530324901 @default.
• W2153032490 hasRelatedWork W2009425390 @default.
• W2153032490 hasRelatedWork W2026728278 @default.

• next